DNA Under the Scope, and a Forensic Tool Under a Cloud
By Carl Zimmer,
The New York Times
| 02. 26. 2016
Untitled Document
Marina Stajic worked for nearly three decades as director of the forensic toxicology lab at the medical examiner’s office in New York City. Last week Dr.. Stajic, 66, filed a lawsuit against the city, claiming she had been forced into retirement last year in part because of a disagreement with her superiors over the accuracy of certain DNA tests.
There is more at stake here than Dr. Stajic’s retirement. The cutting-edge technique at the center of this legal dispute, called low copy number DNA analysis, has transformed not just police work, but also a range of scientific fields including cancer biology, in vitro fertilization, archaeology and evolutionary biology. Yet some of the technique’s applications have triggered scientific controversy.
The medical examiner’s office has become a strong advocate for the technique. It is the only public lab in the United States that uses low copy number DNA to develop profiles for use in criminal cases. But experts have long warned that investigators must take particular care in interpreting these tests: analyzing so few DNA molecules can lead to errors...
Related Articles
It’s been a busy couple of months in biopolitics, with developments in the US, UK, China, Japan, and implicitly on Mars. Time for a brief roundup.
• • •
Bioethics needs an update
The National Research Act is now 50 years old. It was signed into law on July 12, 1974, as a direct response to publicity about the 1932 “Tuskegee Study of Untreated Syphilis in the Negro Male.” The Hastings Bioethics Forum celebrated its anniversary with an...
By Robert Resta, The DNA Exchange | 07.22.2024
Medical geneticists and genetic counselors have an often complicated and at times tense relationship with people with disabilities, their families, advocates, and scholars. Geneticists are strong advocates and supporters for all of their patients, regardless of their abilities and disabilities...
By Katherine Bourzac, Nature | 07.10.2024
Image courtesy National Human Genome Research Institute
The U.S. Food and Drug Administration (FDA) is supposed to encourage effective medical advances while also ensuring that patients and research subjects are protected. This dual mandate demands tricky judgment calls that are made more difficult by outside pressures of several kinds, political, judicial, and especially commercial. This April story at Bloomberg examines one deeply troubling pattern of regulatory capture:
Americans Are Paying Billions to Take Drugs That Don’t Work
Companies are increasingly...